Safety Study of 89Zr-NY001 PET Imaging in Patients

Solid Tumor, Adult Clinical Trial

Official title:

Safety Study of 89Zr-NY001 PET Imaging in Patients With Fibronectin ED-B Positive Solid Tumors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04971369
• Other study ID #: Wuxi-4 PH NY001
• Status: Not yet recruiting
• Phase: N/A
• Start date: August 1, 2021
• Est. completion date: December 31, 2022

Study information

• Verified date: July 2021
• Source: Wuxi No. 4 People's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled NY001 (89Zr-NY001) PET imaging in patients with fibronectin ED-B domain positive solid tumors.

Description:

After being fully informed about the study and potential risks, all patients giving written informed consent will be evaluated to determine eligibility for study entry. Patients will receive an injection of 89Zr-NY001 and will undergo PET/CT scanning to determine uptake of 89Zr-NY001 in tumor lesions and the whole body.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients voluntarily signed informed consent;

2. Aged >18, male or female;

3. Patients diagnosed with solid tumors confirmed by histopathology or cytology test;

4. At least two measurable solid lesions has been examined by 18F-FDG PET/CT (RECIST1.1 standard);

5. Patients with biopsy-proven fibronectin ED-B positive;

6. ECOG score = 0~3; Life expectancy of at least 3 months;

7. Women of childbearing age are required to receive serum pregnancy tests, and only those who have a negative pregnancy test for eligible subjects;

8. ALT, AST shall not exceed 3 times of the normal upper limit; Bun, Cr not exceed 1.5 times of the normal upper limit;

9. Other routine examinations are within the normal range or considered acceptable by the researchers.

Exclusion Criteria:

1. Recovery from major trauma (including surgery) within 4 weeks prior to study treatment;

2. Patients with systemic or locally severe infections, or other serious coexisting diseases;

3. Patients with allergies or allergies to any component of the imaging agent or antibody;

4. Patients who cannot perform PET/CT imaging scan;

5. Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines;

6. Patients with autoimmune diseases, including rheumatoid arthritis;

7. Inadequate control of arrhythmias, including atrial fibrillation;

8. Uncontrolled hypertension;

9. Syphilis, HBV, HCV, or HIV positive subjects;

10. Male and female subjects of reproductive age cannot take effective contraceptive measures;

11. Pregnant or lactating women;

12. Patients with a history of mental illness or related conditions;

13. Other subjects considered unsuitable by researchers.

Related Conditions & MeSH terms

• Solid Tumor, Adult

Intervention

Diagnostic Test:
• 89Zr-NY001
89Zr-NY001 injection followed by 89Zr-NY001 PET scan

Locations

Country	Name	City	State
China	Wuxi No. 4 People's Hospital	Wuxi	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Wuxi No. 4 People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Focal lesion of 89Zr-NY001 PET scanning in patients with fibronectin ED-B domain positive solid tumors.	Degree and localization of focal lesion compared with that of 18F-FDG PET scans and according to the expression of fibronectin ED-B domain will be reported.	1 year